Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mut...

Full description

Bibliographic Details
Main Authors: Van Emburgh, Beth O., Arena, Sabrina, Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Corti, Giorgio, Mussolin, Benedetta, Baldi, Federica, Buscarino, Michela, Bartolini, Alice, Valtorta, Emanuele, Vidal, Joana, Bellosillo, Beatriz, Germano, Giovanni, Pietrantonio, Filippo, Ponzetti, Agostino, Albanell, Joan, Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Montagut, Clara, Bardelli, Alberto
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155160/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155160/

Similar Items